It can assess patients’ suitability for Amgen’s colorectal cancer drug, Vectibix. Canadian regulatory authorities approved DxS’ TheraScreen K-RAS Mutation Kit for use as a diagnostic for anti-EGFR ...
Company will work with ImClone and BMS to develop FDA-approved test for mCRC patients. DxS is to work with ImClone Systems and Bristol-Myers Squibb on the development of a companion diagnostic for the ...
QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) today announced the regulatory approval of its therascreen ® EGFR Mutation Detection Kit RGQ in Japan. EGFR, the epidermal growth factor receptor, ...
LOS ANGELES, Oct. 3, 2023 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has granted approval for EntroGen's CRCdx® RAS Mutation Detection Kit as a companion diagnostic for Vectibix® ...
Dublin, Oct. 14, 2025 (GLOBE NEWSWIRE) -- The "Mutation Detection Kits in Genome Editing Market Report 2025" has been added to ResearchAndMarkets.com's offering. The mutation detection kits in the ...
The US Food and Drug Administration (FDA) has granted approval for EntroGen's CRCdx RAS Mutation Detection Kit as a companion diagnostic for Vectibix (panitumumab), a targeted therapy used in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results